Ionis Pharmaceuticals, Inc.
Methods for modulating Ataxin 2 expression

Last updated:

Abstract:

Disclosed herein are methods for decreasing Ataxin 2 mRNA and protein expression. Such methods are useful to treat, prevent, or ameliorate Ataxin 2 associated diseases, disorders, and conditions. Such Ataxin 2 associated diseases include spinocerebellar ataxia type 2 (SCA2), amyotrophic lateral sclerosis (ALS), and parkinsonism.

Status:
Grant
Type:

Utility

Filling date:

7 May 2018

Issue date:

14 Jan 2020